Browse by ▼

Osiris Therapeutics, Inc.

  • Safe Stem Cell Therapy for Healing Is Still a Strong Bet

    By Shas Dey - May 7, 2013 | Tickers: ATHX, CYTX, OSIR

    MultiStem cell therapy being developed by Athersys (NASDAQ: ATHX) has excited people because of the advantages and sophistication levels it possesses over existing stem cell therapies. Big pharma is betting on this new therapy; let us find out why.

    MultiStem – not a cure-all but a relatively potent therapy

    The popular belief is that since stem cell therapy is a cure-all therapy as it involves removing and replacement of the malfunctioning more »

  • Three Value Traps That Reported Earnings on Wednesday

    By Brian Nichols - March 7, 2013 | Tickers: OSIR, QIHU, PAY

    After a 70% return during the last year, shares of Chinese internet based company Qihoo 360 Technology (NYSE: QIHU) traded lower by 7.55% after reporting earnings. The company actually beat on both the top and bottom line, with revenue of $103 million, a 65% gain year-over-year (yoy) and $9.32 million better than the consensus, and an EPS of $0.22, beating expectation by $0.05. In addition the more »

  • Stem Cell Therapy—Breakthrough in Health Paradigm

    By Sharmistha Banerjee - September 25, 2012 | Tickers: NBS, OSIR, PSTI

    Far-reaching accomplishments in the biotechnology sector meet its most ambitious expectations, stem cell therapy. The birth of this new industry has boosted the enthusiasm and energy of investors and has brought unprecedented capability and optimistic predictions. New developments in regenerative medicine are bringing about exciting, novel approaches to create therapies for hard to treat diseases. The biotechnology industry has been soaring in 2012 as companies both large and small have more »

  • Immortality and 3 Stem Cell Research Stocks

    By Karen Rogers - September 21, 2012 | Tickers: BAX, NBS, OSIR

    Stem cell research puts immortality in our hands.  By medically treating stem cells to repair damaged organs, one could, in theory, live forever.  The following three stem cell research companies are achingly close to perfecting techniques that will repair and strengthen damaged human hearts.         

    Osiris Therapeutics’ (NASDAQ: OSIR) Prochymal is the only drug that’s been granted fast track status and Orphan Drug status by the FDA.  Already in Phase more »

  • Stem Cell Therapy Space Worth Review for Investors

    By Tedra DeSue - August 3, 2012 | Tickers: BAX, OSIR

    Advances continue to be made in the field of regenerative medicine, with many products and procedures being made possible from stem cell therapy. While large companies are making headway in this area, many small companies are just as active, raising much-needed funds through the capital markets.

    The main challenge all of these companies face is convincing naysayers that their research and subsequent results are ethical. There has been much ado more »